Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects Aged 18-59 Years

NCT05805618 is registered in ClinicalTrials.gov with Syneos Health as lead sponsor.

NCT NCT05805618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05805618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects Aged 18-59 Years
Lead sponsor
Syneos Health
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2024
Completion date
November 1, 2024
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteritis